BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11590304)

  • 1. Rofecoxib: a new selective COX-2 inhibitor.
    Rajadhyaksha VD; Dahanukar SA
    J Postgrad Med; 2001; 47(1):77-8. PubMed ID: 11590304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
    MMW Fortschr Med; 2003 Aug; 145(31-32):56-7. PubMed ID: 14524083
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
    MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601
    [No Abstract]   [Full Text] [Related]  

  • 4. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A
    J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain].
    Morović-Vergles J
    Reumatizam; 2003; 50(2):47-8. PubMed ID: 15098376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 9. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
    Ahuja N; Singh A; Singh B
    J Pharm Pharmacol; 2003 Jul; 55(7):859-94. PubMed ID: 12906745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why don't we initiate more large simple randomized controlled trials?
    Wright JM
    CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on efficacy of rofecoxib and nimesulide in controlling post-extraction pain in oral surgery: a randomised comparative study.
    Villa G
    Curr Med Res Opin; 2004 Apr; 20(4):573-4; author reply 574. PubMed ID: 15119995
    [No Abstract]   [Full Text] [Related]  

  • 12. An update on specific COX-2 inhibitors: the COXIBs.
    Gupta S; Crofford LJ
    Bull Rheum Dis; 2001; 50(1):1-4. PubMed ID: 12092091
    [No Abstract]   [Full Text] [Related]  

  • 13. [Meta-analysis on acute pain. Rofecoxib helped three quarters of patients].
    MMW Fortschr Med; 2003 Aug; 145(31-32):57. PubMed ID: 14524084
    [No Abstract]   [Full Text] [Related]  

  • 14. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 17. [Selective COX-2 inhibitors--strong medicine for pain].
    MMW Fortschr Med; 2004 Apr; 146(17):56-7. PubMed ID: 15224910
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
    MMW Fortschr Med; 2002 Feb; 144(7):68. PubMed ID: 11887740
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
    Sánchez-Fidalgo S; Martín-Lacave I; Illanes M; Motilva V
    Eur J Pharmacol; 2004 Nov; 505(1-3):187-94. PubMed ID: 15556152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.